SWK Holdings Corp. 9% Preferred Stock (SWKHL)

Overview

SWK Holdings Corporation is a specialized finance entity dedicated to the healthcare sector. Operating in two main segments, Finance Receivables and Pharmaceutical Development, the company offers an array of financing solutions targeted towards life science companies. These companies range across the biotechnology, medical device, medical diagnostics, animal health, and pharmaceutical industries, including institutions and inventors. Initially known as Kana Software, Inc., the company underwent a name change to SWK Holdings Corporation in December 2009. Since its inception in 1996, it has been headquartered in Dallas, Texas. SWK Holdings Corporation extends beyond financing, providing non-discretionary investment advisory services to institutional clients and engaging in pharmaceutical development through initiatives like the Peptelligence platform, alongside planning to out-license its internal product pipeline to foster novel treatments.

Products and Services

• Finance Receivables: This segment encompasses the provision of customized financing solutions catered to the vast spectrum of companies operating within the life sciences domain. These solutions are designed to support the unique financial needs of entities involved in biotechnology, medical devices, diagnostics, animal health, and pharmaceuticals, facilitating their growth and development.
• Pharmaceutical Development: SWK Holdings engages in significant pharmaceutical development activities. This includes formulation and manufacturing underpinned by its proprietary Peptelligence platform. This platform and its ensuing activities underscore the company's commitment to creating novel formulations which may lead to the development of new treatments for patients and caregivers.
• Investment Advisory Services: Offering non-discretionary investment advisory services, SWK Holdings caters to institutional clients through separately managed accounts. These services focus on investments in life science finance, leveraging the significant potential and growth opportunities within this sector to provide value to its institutional clients.
• Peptelligence Platform: A cornerstone of its pharmaceutical development segment, the Peptelligence platform specializes in the development, formulation, and manufacturing processes of pharmaceutical products. Through this proprietary technology, SWK Holdings intends to out-license its internal product pipeline, thereby creating innovative formulations that facilitate the development of new treatments tailored to both patients and caregivers’ needs.